228 related articles for article (PubMed ID: 30845361)
1. Effects of proton pump inhibitors, esomeprazole and vonoprazan, on the disposition of proguanil, a CYP2C19 substrate, in healthy volunteers.
Funakoshi R; Tomoda Y; Kudo T; Furihata K; Kusuhara H; Ito K
Br J Clin Pharmacol; 2019 Jul; 85(7):1454-1463. PubMed ID: 30845361
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of CYP2C19-Mediated Pharmacokinetic Drug Interaction of Tegoprazan, Compared with Vonoprazan or Esomeprazole.
Yang E; Ji SC; Jang IJ; Lee S
Clin Pharmacokinet; 2023 Apr; 62(4):599-608. PubMed ID: 36897544
[TBL] [Abstract][Full Text] [Related]
3. Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype.
Kagami T; Sahara S; Ichikawa H; Uotani T; Yamade M; Sugimoto M; Hamaya Y; Iwaizumi M; Osawa S; Sugimoto K; Miyajima H; Furuta T
Aliment Pharmacol Ther; 2016 May; 43(10):1048-59. PubMed ID: 26991399
[TBL] [Abstract][Full Text] [Related]
4. The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations.
Echizen H
Clin Pharmacokinet; 2016 Apr; 55(4):409-18. PubMed ID: 26369775
[TBL] [Abstract][Full Text] [Related]
5. Night-time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole.
Yang E; Kim S; Kim B; Kim B; Kim Y; Park SS; Song GS; Yu KS; Jang IJ; Lee S
Br J Clin Pharmacol; 2022 Jul; 88(7):3288-3296. PubMed ID: 35146797
[TBL] [Abstract][Full Text] [Related]
6. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects--a randomised open-label cross-over study.
Sakurai Y; Mori Y; Okamoto H; Nishimura A; Komura E; Araki T; Shiramoto M
Aliment Pharmacol Ther; 2015 Sep; 42(6):719-30. PubMed ID: 26193978
[TBL] [Abstract][Full Text] [Related]
7. Comparative Study of Effects of Vonoprazan and Esomeprazole on Antiplatelet Function of Clopidogrel or Prasugrel in Relation to CYP2C19 Genotype.
Kagami T; Yamade M; Suzuki T; Uotani T; Hamaya Y; Iwaizumi M; Osawa S; Sugimoto K; Umemura K; Miyajima H; Furuta T
Clin Pharmacol Ther; 2018 May; 103(5):906-913. PubMed ID: 28875498
[TBL] [Abstract][Full Text] [Related]
8. Effect of High-Dose Esomeprazole on CYP1A2, CYP2C19, and CYP3A4 Activities in Humans: Evidence for Substantial and Long-lasting Inhibition of CYP2C19.
Kaartinen TJK; Tornio A; Tapaninen T; Launiainen T; Isoherranen N; Niemi M; Backman JT
Clin Pharmacol Ther; 2020 Dec; 108(6):1254-1264. PubMed ID: 32558923
[TBL] [Abstract][Full Text] [Related]
9. CYP2C19*17 increases clopidogrel-mediated platelet inhibition but does not alter the pharmacokinetics of the active metabolite of clopidogrel.
Pedersen RS; Nielsen F; Stage TB; Vinholt PJ; el Achwah AB; Damkier P; Brosen K
Clin Exp Pharmacol Physiol; 2014 Nov; 41(11):870-8. PubMed ID: 25115434
[TBL] [Abstract][Full Text] [Related]
10. The Effects of Switching to Vonoprazan, a Novel Potassium-Competitive Acid Blocker, on Gastric Acidity and Reflux Patterns in Patients with Erosive Esophagitis Refractory to Proton Pump Inhibitors.
Yamashita H; Kanamori A; Kano C; Hashimura H; Matsumoto K; Tsujimae M; Yoshizaki T; Momose K; Obata D; Eguchi T; Fujita M; Okada A
Digestion; 2017; 96(1):52-59. PubMed ID: 28662503
[TBL] [Abstract][Full Text] [Related]
11. Inhibition by omeprazole of proguanil metabolism: mechanism of the interaction in vitro and prediction of in vivo results from the in vitro experiments.
Funck-Brentano C; Becquemont L; Lenevu A; Roux A; Jaillon P; Beaune P
J Pharmacol Exp Ther; 1997 Feb; 280(2):730-8. PubMed ID: 9023285
[TBL] [Abstract][Full Text] [Related]
12. Cost-utility analysis of a 'vonoprazan-first' strategy versus 'esomeprazole- or rabeprazole-first' strategy in GERD.
Yokoya Y; Igarashi A; Uda A; Deguchi H; Takeuchi T; Higuchi K
J Gastroenterol; 2019 Dec; 54(12):1083-1095. PubMed ID: 31396703
[TBL] [Abstract][Full Text] [Related]
13. Vonoprazan, a Novel Potassium-Competitive Acid Blocker, Should Be Used for the Helicobacter pylori Eradication Therapy as First Choice: A Large Sample Study of Vonoprazan in Real World Compared with Our Randomized Control Trial Using Second-Generation Proton Pump Inhibitors for Helicobacter pylori Eradication Therapy.
Ozaki H; Harada S; Takeuchi T; Kawaguchi S; Takahashi Y; Kojima Y; Ota K; Hongo Y; Ashida K; Sakaguchi M; Tokioka S; Sakamoto H; Furuta T; Tominaga K; Higuchi K
Digestion; 2018; 97(3):212-218. PubMed ID: 29393194
[TBL] [Abstract][Full Text] [Related]
14. Time-dependent pharmacokinetics and drug metabolism of atovaquone plus proguanil (Malarone) when taken as chemoprophylaxis.
Thapar MM; Ashton M; Lindegårdh N; Bergqvist Y; Nivelius S; Johansson I; Björkman A
Eur J Clin Pharmacol; 2002 Apr; 58(1):19-27. PubMed ID: 11956669
[TBL] [Abstract][Full Text] [Related]
15. Changes in CYP2C19 enzyme activity evaluated by the [(13)C]-pantoprazole breath test after co-administration of clopidogrel and proton pump inhibitors following percutaneous coronary intervention and correlation to platelet reactivity.
Harvey A; Modak A; Déry U; Roy M; Rinfret S; Bertrand OF; Larose É; Rodés-Cabau J; Barbeau G; Gleeton O; Nguyen CM; Proulx G; Noël B; Roy L; Paradis JM; De Larochellière R; Déry JP
J Breath Res; 2016 Jan; 10(1):017104. PubMed ID: 26815196
[TBL] [Abstract][Full Text] [Related]
16. Steady-state kinetics of proguanil and its active metabolite, cycloguanil, in man.
Edstein MD; Veenendaal JR; Scott HV; Rieckmann KH
Chemotherapy; 1988; 34(5):385-92. PubMed ID: 3180907
[TBL] [Abstract][Full Text] [Related]
17. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.
Frelinger AL; Lee RD; Mulford DJ; Wu J; Nudurupati S; Nigam A; Brooks JK; Bhatt DL; Michelson AD
J Am Coll Cardiol; 2012 Apr; 59(14):1304-11. PubMed ID: 22464259
[TBL] [Abstract][Full Text] [Related]
18. In Vitro Assessment of Potential for CYP-Inhibition-Based Drug-Drug Interaction Between Vonoprazan and Clopidogrel.
Nishihara M; Yamasaki H; Czerniak R; Jenkins H
Eur J Drug Metab Pharmacokinet; 2019 Apr; 44(2):217-227. PubMed ID: 30361928
[TBL] [Abstract][Full Text] [Related]
19. Proguanil disposition and toxicity in malaria patients from Vanuatu with high frequencies of CYP2C19 mutations.
Kaneko A; Bergqvist Y; Taleo G; Kobayakawa T; Ishizaki T; Björkman A
Pharmacogenetics; 1999 Jun; 9(3):317-26. PubMed ID: 10471063
[TBL] [Abstract][Full Text] [Related]
20. Comparison of (S)-mephenytoin and proguanil oxidation in vitro: contribution of several CYP isoforms.
Coller JK; Somogyi AA; Bochner F
Br J Clin Pharmacol; 1999 Aug; 48(2):158-67. PubMed ID: 10417492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
